Soleno Therapeutics received FDA approval for Vykat XR that triggered an increase in its biotech stock value against other rare disease treatment competitors.

The FDA approved Soleno Therapeutics to market Vykat XR as a pharmaceutical drug that treats hunger symptoms within Prader-Willi syndrome patients. The achievement prompted biotech stock appreciation of 37.6% which resulted in a $67.39 closing price past its key buy point.

The extended-release tablet Vykat XR becomes available to patients beginning at age four during April. The biotech industry views this approval as a major accomplishment since Soleno needed to show patients lost their symptoms after removing treatment to get FDA authorization.

This drug approval received close attention from the biotech industry because the yearly prescription price amounts to $486,000. Analysts predict that competition will emerge in the market from Aardvark Therapeutics because they are developing ARD-101 that presents its own unique benefit-risk characteristics.

Even though researchers have detected hyperglycemia and excessive hair growth as treatment side effects they expect these biotech medicines to exist simultaneously for Prader-Willi syndrome management.

Aardvark recorded initial stock appreciation after Soleno's approval until market hesitancy caused its value to decrease 5.5%. The biotech sector continues its research into rare diseases and regulatory and commercial hurdles by this newly developed product..